A biohasonló gyógyszerek árversenyének tapasztalatai Magyarországon

Translated title of the contribution: Experiences with price competition of biosimilar drugs in Hungary

Lajos Hornyák, Zsolt Nagy, Zsuzsanna Tálos, Dóra Endrei, István Ágoston, Tímea Csákvári, I. Boncz

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Aim: The aim of our study is to analyse the biosimilar bids of the Hungarian National Health Insurance Fund Administration in case of colony-stimulating factor and erythropoietin products. Data and methods: Data derived from the nationwide pharmaceutical database of Hungarian National Health Insurance Fund Administration. We analysed how the number of patients treated by colony-stimulating factor and erythropoietin products changed before (01.07.2011.-30.06.2012.) and after (01.07.2012.-30.06.2013.) the first biosimilar bid performed in March 2012 in Hungary. Results: In the 12 months before biosimilar bid 4167 patients received erythropoietin treatment, while in the first 12 months after the bid 3647 patients, resulting in a 12.5% decline. In the 12 months before biosimilar bid 13974 patients received colony-stimulating factor treatment, while in the first 12 months after the bid 13352 patients, resulting in a 4.5% decline. Conclusions: The analyses of the Hungarian price competition bid of biosimilar products showed a minimal decline in the number of patients under treatment by both colony-stimulating factor and erythropoietin products while the health insurance reimbursement of these drugs significantly decreased.

Original languageHungarian
Pages (from-to)83-87
Number of pages5
JournalActa Pharmaceutica Hungarica
Volume84
Issue number2
Publication statusPublished - 2014

Fingerprint

Biosimilar Pharmaceuticals
Hungary
Colony-Stimulating Factors
Erythropoietin
Pharmaceutical Preparations
National Health Programs
Pharmaceutical Databases
Health Insurance Reimbursement
Therapeutics

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Hornyák, L., Nagy, Z., Tálos, Z., Endrei, D., Ágoston, I., Csákvári, T., & Boncz, I. (2014). A biohasonló gyógyszerek árversenyének tapasztalatai Magyarországon. Acta Pharmaceutica Hungarica, 84(2), 83-87.

A biohasonló gyógyszerek árversenyének tapasztalatai Magyarországon. / Hornyák, Lajos; Nagy, Zsolt; Tálos, Zsuzsanna; Endrei, Dóra; Ágoston, István; Csákvári, Tímea; Boncz, I.

In: Acta Pharmaceutica Hungarica, Vol. 84, No. 2, 2014, p. 83-87.

Research output: Contribution to journalArticle

Hornyák, L, Nagy, Z, Tálos, Z, Endrei, D, Ágoston, I, Csákvári, T & Boncz, I 2014, 'A biohasonló gyógyszerek árversenyének tapasztalatai Magyarországon', Acta Pharmaceutica Hungarica, vol. 84, no. 2, pp. 83-87.
Hornyák L, Nagy Z, Tálos Z, Endrei D, Ágoston I, Csákvári T et al. A biohasonló gyógyszerek árversenyének tapasztalatai Magyarországon. Acta Pharmaceutica Hungarica. 2014;84(2):83-87.
Hornyák, Lajos ; Nagy, Zsolt ; Tálos, Zsuzsanna ; Endrei, Dóra ; Ágoston, István ; Csákvári, Tímea ; Boncz, I. / A biohasonló gyógyszerek árversenyének tapasztalatai Magyarországon. In: Acta Pharmaceutica Hungarica. 2014 ; Vol. 84, No. 2. pp. 83-87.
@article{020ee4e160654d3fabac728a42b6faeb,
title = "A biohasonl{\'o} gy{\'o}gyszerek {\'a}rverseny{\'e}nek tapasztalatai Magyarorsz{\'a}gon",
abstract = "Aim: The aim of our study is to analyse the biosimilar bids of the Hungarian National Health Insurance Fund Administration in case of colony-stimulating factor and erythropoietin products. Data and methods: Data derived from the nationwide pharmaceutical database of Hungarian National Health Insurance Fund Administration. We analysed how the number of patients treated by colony-stimulating factor and erythropoietin products changed before (01.07.2011.-30.06.2012.) and after (01.07.2012.-30.06.2013.) the first biosimilar bid performed in March 2012 in Hungary. Results: In the 12 months before biosimilar bid 4167 patients received erythropoietin treatment, while in the first 12 months after the bid 3647 patients, resulting in a 12.5{\%} decline. In the 12 months before biosimilar bid 13974 patients received colony-stimulating factor treatment, while in the first 12 months after the bid 13352 patients, resulting in a 4.5{\%} decline. Conclusions: The analyses of the Hungarian price competition bid of biosimilar products showed a minimal decline in the number of patients under treatment by both colony-stimulating factor and erythropoietin products while the health insurance reimbursement of these drugs significantly decreased.",
keywords = "Access, Bid, Biosimilar, Drug market, Price competition, Reimbursement",
author = "Lajos Horny{\'a}k and Zsolt Nagy and Zsuzsanna T{\'a}los and D{\'o}ra Endrei and Istv{\'a}n {\'A}goston and T{\'i}mea Cs{\'a}kv{\'a}ri and I. Boncz",
year = "2014",
language = "Hungarian",
volume = "84",
pages = "83--87",
journal = "Acta Pharmaceutica Hungarica",
issn = "0001-6659",
publisher = "Magyar Gyogyszereszeti Tarsasag",
number = "2",

}

TY - JOUR

T1 - A biohasonló gyógyszerek árversenyének tapasztalatai Magyarországon

AU - Hornyák, Lajos

AU - Nagy, Zsolt

AU - Tálos, Zsuzsanna

AU - Endrei, Dóra

AU - Ágoston, István

AU - Csákvári, Tímea

AU - Boncz, I.

PY - 2014

Y1 - 2014

N2 - Aim: The aim of our study is to analyse the biosimilar bids of the Hungarian National Health Insurance Fund Administration in case of colony-stimulating factor and erythropoietin products. Data and methods: Data derived from the nationwide pharmaceutical database of Hungarian National Health Insurance Fund Administration. We analysed how the number of patients treated by colony-stimulating factor and erythropoietin products changed before (01.07.2011.-30.06.2012.) and after (01.07.2012.-30.06.2013.) the first biosimilar bid performed in March 2012 in Hungary. Results: In the 12 months before biosimilar bid 4167 patients received erythropoietin treatment, while in the first 12 months after the bid 3647 patients, resulting in a 12.5% decline. In the 12 months before biosimilar bid 13974 patients received colony-stimulating factor treatment, while in the first 12 months after the bid 13352 patients, resulting in a 4.5% decline. Conclusions: The analyses of the Hungarian price competition bid of biosimilar products showed a minimal decline in the number of patients under treatment by both colony-stimulating factor and erythropoietin products while the health insurance reimbursement of these drugs significantly decreased.

AB - Aim: The aim of our study is to analyse the biosimilar bids of the Hungarian National Health Insurance Fund Administration in case of colony-stimulating factor and erythropoietin products. Data and methods: Data derived from the nationwide pharmaceutical database of Hungarian National Health Insurance Fund Administration. We analysed how the number of patients treated by colony-stimulating factor and erythropoietin products changed before (01.07.2011.-30.06.2012.) and after (01.07.2012.-30.06.2013.) the first biosimilar bid performed in March 2012 in Hungary. Results: In the 12 months before biosimilar bid 4167 patients received erythropoietin treatment, while in the first 12 months after the bid 3647 patients, resulting in a 12.5% decline. In the 12 months before biosimilar bid 13974 patients received colony-stimulating factor treatment, while in the first 12 months after the bid 13352 patients, resulting in a 4.5% decline. Conclusions: The analyses of the Hungarian price competition bid of biosimilar products showed a minimal decline in the number of patients under treatment by both colony-stimulating factor and erythropoietin products while the health insurance reimbursement of these drugs significantly decreased.

KW - Access

KW - Bid

KW - Biosimilar

KW - Drug market

KW - Price competition

KW - Reimbursement

UR - http://www.scopus.com/inward/record.url?scp=84905086169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905086169&partnerID=8YFLogxK

M3 - Article

VL - 84

SP - 83

EP - 87

JO - Acta Pharmaceutica Hungarica

JF - Acta Pharmaceutica Hungarica

SN - 0001-6659

IS - 2

ER -